Pancreatic cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• KRAS 67
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• BRAF 2
• MET 2
• TROP2 3
• B7-H3 2
• CDK4/6 0
• FGFR 1
• HSP90 0
• CTNNB1 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• NTRK 1
• RET 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 9,790 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT05723107· NYU Langone Health· Updated 6 Nov 2026

  “Halted prematurely”Registry text, quoted unchanged. Source

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Suspended

  TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

  NCT07377526· M.D. Anderson Cancer Center· Updated 3 Nov 2026

  “PI Request”Registry text, quoted unchanged. Source

• Suspended

  CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

  NCT05685602· National Cancer Institute (NCI)· Updated 3 Nov 2026

  “Drug Supply Issues”Registry text, quoted unchanged. Source

• Terminated

  Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

  NCT05911243· University of Washington· Updated 3 Nov 2026

  “Study closed per SRC Low Accrual Policy.”Registry text, quoted unchanged. Source

• Terminated

  huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

  NCT05057715· University of Pennsylvania· Updated 29 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Suspended

  A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

  NCT04111172· Thomas Jefferson University· Updated 28 Oct 2026

  “Protocol is with FDA review, waiting for funding to be released”Registry text, quoted unchanged. Source

• Terminated

  ZN-c3 + Gemcitabine in Pancreatic Cancer

  NCT06015659· Brandon Huffman, MD· Updated 27 Oct 2026

  “Study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.”Registry text, quoted unchanged. Source

• Terminated

  Pilot Study of Pancreatic Cancer Screening

  NCT05058846· University of California, San Francisco· Updated 26 Oct 2026

  “Slow accrual”Registry text, quoted unchanged. Source

• Terminated

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Updated 23 Oct 2026

  “Company's strategic decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT05723107· NYU Langone Health· Source

• The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· National Cancer Institute (NCI)· Source

• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

  NCT01950572· National Cancer Institute (NCI)· Source

• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  NCT04172532· National Cancer Institute (NCI)· Source

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Source

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

  NCT06885697· National Cancer Institute (NCI)· Source

• A Decision Support Tool for Pancreatic Cancer Screening -Aim 2

  NCT07808671· UNC Lineberger Comprehensive Cancer Center· Source

• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  NCT04858334· National Cancer Institute (NCI)· Source

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 46
• Mendelian Randomization Analysis 28
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 54
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 28
• Xenograft Model Antitumor Assays 298
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 116
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

See which targets of this disease your abstract mentions, and go to the people working on them.